ITM gains rights to theranostics pair for solid tumors

ITM Isotope Technologies Munich has secured an exclusive global license for the clinical and commercial development of Debiopharm’s cancer imaging and treatment pair ITM-91/ITM-94D.

Formerly known as Debio 0228/0328, ITM-91/ITM-94D targets a surface protein expressed on solid tumors. ITM-91 is a lutetium-177-labeled radioligand therapeutic compound and ITM-94D is a gallium-68-labeled imaging agent. The pair is being investigated in the phase I/II clinical trial in patients with clear cell renal cell carcinoma, pancreatic ductal adenocarcinoma, and colorectal cancer.

Under the agreement, Debiopharm will receive payments of approximately $331 million, as well as commercial milestones and royalties on potential future sales, ITM said.

Page 1 of 597
Next Page